» Articles » PMID: 39441131

Clinically Appropriate Dose Reductions and Interruptions Do Not Compromise Efficacy in Patients Receiving Treatment with Ibrutinib

Overview
Journal Leuk Lymphoma
Specialties Hematology
Oncology
Date 2024 Oct 23
PMID 39441131
Authors
Affiliations
Soon will be listed here.